- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00636636
Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary study objective is to assess the relative efficacy of G-ER dosed once daily (1800 mg following the evening meal), versus placebo in reducing the mean daily pain score from the baseline week to the end of the efficacy treatment period (Treatment Week 10) in patients with PHN.
Secondary efficacy measures will include changes from baseline in mean weekly sleep interference scores, Short-Form McGill Pain Questionnaire (SF-MPQ), the Neuropathic Pain Scale (NPS), Brief Pain Inventory (BPI), Patient Global Impression of Change (PGIC), and Investigator-Rated Clinical Global Impression of Change (CGIC).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
-
-
-
-
-
All over Russia, Russian Federation
-
St. Petersburg, Russian Federation
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
Tuscaloosa, Alabama, United States
-
-
Arizona
-
Phoenix, Arizona, United States
-
-
Arkansas
-
Little Rock, Arkansas, United States
-
-
California
-
Lancaster, California, United States
-
Los Angeles, California, United States
-
Pismo Beach, California, United States
-
-
Colorado
-
Colorado Springs, Colorado, United States
-
Pueblo, Colorado, United States
-
-
Florida
-
Daytona Beach, Florida, United States
-
Naples, Florida, United States
-
New Port Richey, Florida, United States
-
Orlando, Florida, United States
-
Tampa, Florida, United States
-
-
Georgia
-
Marietta, Georgia, United States
-
-
Hawaii
-
Honolulu, Hawaii, United States
-
-
Illinois
-
Elk Grove Village, Illinois, United States
-
-
Louisiana
-
Shreveport, Louisiana, United States
-
-
Massachusetts
-
West Yarmouth, Massachusetts, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States
-
-
Missouri
-
Florissant, Missouri, United States
-
Jefferson City, Missouri, United States
-
-
New Mexico
-
Albuquerque, New Mexico, United States
-
-
North Carolina
-
High Point, North Carolina, United States
-
-
North Dakota
-
Bismarck, North Dakota, United States
-
Fargo, North Dakota, United States
-
-
Ohio
-
Canton, Ohio, United States
-
Cincinnati, Ohio, United States
-
Kettering, Ohio, United States
-
-
Rhode Island
-
Warwick, Rhode Island, United States
-
-
South Carolina
-
Murrells Inlet, South Carolina, United States
-
Pelzer, South Carolina, United States
-
-
Tennessee
-
Tullahoma, Tennessee, United States
-
-
Texas
-
Austin, Texas, United States
-
Longview, Texas, United States
-
-
Washington
-
Spokane, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women 18 years or older who have experienced pain for at least 6 months, but not more than 5 years after the healing of a herpes zoster skin rash(typically about 4 months after the rash first appears).
- Patient has a pain intensity score of at least 4 on the 11-point Numerical Rating Scale (NRS). Patients should never be informed of the pain intensity criterion prior to screening or randomization.
- Patients of child-bearing potential must have a negative serum pregnancy test at screening and a negative follow-up urine pregnancy test at randomization.
- Patient has a mean baseline week pain intensity score of at least 4 on the 11-point NRS scale at the end of a 1-week baseline period and has completed at least 4 days of daily pain diary entries during the baseline week.
- Patients must have a minimum washout period of greater than 5 times the half-life of the drug of several medications.
- Patients currently treated with gabapentin pr pregabalin at screening may be eligible for the study, but must have a tapering period wherein the dose of gabapentin or pregabalin is reduced gradually over a period of 5 days followed by a two day washout prior to the Baseline Week.
Exclusion Criteria:
- Patients who have previously not responded to treatment for PHN with gabapentin or pregabalin.
- Patients who previously experienced dose-limiting adverse effects that prevented titration of gabapentin to an effective dose.
- Patient is a nursing mother.
- Patient has hypersensitivity to gabapentin.
- Patient has had neurolytic or neurosurgical treatment for PHN.
- Patient has severe pain from causes other than PHN.
- Patient has used injected anesthetics or steroids within 30 days of baseline.
- Patient has skin conditions in the area affected by the neuropathy that could alter sensation.
- Patient is in an immunocompromised state.
- Patient has an estimated creatinine clearance less than 50 ml/min.
- Patient has had malignancy within past 2 years other than basal cell carcinoma.
- Patient has had gastric reduction surgery.
- Patient has severe chronic diarrhea, chronic constipation [unless attributed to drugs that will be washed out], uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss.
- Patient has any abnormal chemistry or hematology results that are deemed by the investigator to be clinically significant.
- Patient has a history of substance abuse within the past year.
- Patient has a history of seizure (except for infantile febrile seizure) or is at risk of seizure due to head trauma.
- Patient has a history of chronic hepatitis B or C, hepatitis within the past 3 months, or HIV infection.
- Patient has any other clinically significant medical or psychological condition that, in the opinion of the Investigator would jeopardize the safety of the patient or affect the validity of the study results.
- Continuing use of any concomitant medication excluded by Inclusion Criterion 5.
- Patient has participated in a clinical trial of an investigational drug or device within 30 days of the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Sugar pill
|
Once daily; 300 mg and 600 mg tablets
|
Experimental: G-ER
Gabapentin - Extended Release
|
Once-Daily; 300 mg and 600 mg tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score
Time Frame: 10 weeks
|
Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain).
Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily pain score from baseline to the final week of efficacy treatment period (Week 10).
|
10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Global Impression of Change (PGIC)
Time Frame: 10 weeks
|
Patient self-assessment of how much pain had changed at end of treatment period (Week 10) compared to pain at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse).
Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).
|
10 weeks
|
Clinical Global Impression of Change (CGIC)
Time Frame: 10 weeks
|
Investigator assessment of patient's overall PHN symptoms at end of treatment period (Week 10) compared to overall PHN symptoms at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse).
Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).
|
10 weeks
|
Average Daily Sleep Interference Score
Time Frame: 10 weeks
|
Assessed on 11-point numeric rating scale (where 0 = pain does not interfere with sleep, 10 = pain completely interferes with sleep); evaluated from daily sleep entry in electronic diary.
Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily sleep interference score from baseline to final week of treatment period (Week 10).
|
10 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Last Observation Carried Forward (LOCF) Average Daily Pain Score
Time Frame: 10 weeks
|
Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain).
Results presented as least squares (LS) mean change in last observation carried forward (LOCF) average daily pain score from baseline to final week of efficacy treatment period (Week 10).
|
10 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Neuralgia
- Neuralgia, Postherpetic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- Anticonvulsants
- Antimanic Agents
- Gabapentin
Other Study ID Numbers
- 81-0062
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuralgia,Postherpetic
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia ( PHN )China
-
Yonsei UniversityWithdrawnThe Evaluation of Erector Spinae Plane Block for the Pain Control of Thoracic Postherpetic NeuralgiaThoracic Postherpetic NeuralgiaKorea, Republic of
-
Shanghai SIMR Biotechnology Co., Ltd.CompletedPostherpetic NeuralgiaChina, Australia
-
Haisco Pharmaceutical Group Co., Ltd.CompletedPostherpetic NeuralgiaChina
-
Cairo UniversityCompleted
-
Korea University Guro HospitalUnknownNeuralgia,PostherpeticKorea, Republic of
-
Second Affiliated Hospital, School of Medicine,...CompletedPostherpetic NeuralgiaChina
-
Cubist Pharmaceuticals LLCPfizerTerminatedPostherpetic NeuralgiaUnited States
-
PfizerTerminatedPostherpetic NeuralgiaUnited States, Germany, Austria, South Africa
-
ZalicusCompletedPostherpetic NeuralgiaUnited States
Clinical Trials on Gabapentin Extended Release tablets
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy (HIBM)United States
-
Johns Hopkins UniversityBaylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple UniversityNot yet recruitingAsthma | Overweight and Obesity | Asthma Chronic
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyUnited States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
-
AbbottRecruitingFunctional DyspepsiaMalaysia, Armenia
-
XenoPort, Inc.CompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
DepomedCompleted
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
AstraZenecaRecruiting